



Hepatitis C (HCV) Enrollment Form

Phone: (706) 849-4161

Fax: (706) 798-9683

PATIENT INFORMATION <i>(Complete or include demographic sheet)</i> Patient Name: _____ DOB: _____ Address: _____ City, State, Zip: _____ Primary Phone: _____ Alternate Phone: _____ Gender: _____ Email: _____ SSN: _____ Allergies: _____		PRESCRIBER INFORMATION Prescriber Name: _____ State License #: _____ NPI#: _____ DEA#: _____ Organization: _____ Address: _____ City, State, Zip: _____ Phone: _____ Fax: _____ Contact Person: _____ Tax ID: _____	
INSURANCE INFORMATION: Please fax/scan the front and back of the insurance card			
DIAGNOSIS AND CLINICAL INFORMATION <i>(Prescriber must provide the following)</i> Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Office <input type="checkbox"/> Other (specify): _____ Diagnosis Date: _____ Starting RNA Titer: _____ Diagnosis (ICD-10 code): _____			
Patient Evaluation: HCV Genotype: <input type="checkbox"/> 1a <input type="checkbox"/> 1b <input type="checkbox"/> 2 <input type="checkbox"/> 3 <input type="checkbox"/> 4 <input type="checkbox"/> 5 <input type="checkbox"/> 6 Height (cm): _____ Weight (kg): _____ Autoimmune hepatitis or another condition known to be exacerbated by interferon or ribavirin? <input type="checkbox"/> Yes <input type="checkbox"/> No Status: <input type="checkbox"/> Naive <input type="checkbox"/> Partial resp. <input type="checkbox"/> Null- resp. <input type="checkbox"/> Non- resp. <input type="checkbox"/> Relapse Last date of therapy: _____ Product Names: _____ Is patient currently on (HCV) therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, Therapy start date: _____ Product names: _____ Requested start date for (HCV) therapy: _____ <input type="checkbox"/> Attached active medication list for pharmacist review Has patient previously failed therapy with a treatment regimen that included a protease inhibitor? <input type="checkbox"/> Yes <input type="checkbox"/> No HIV co-infected <input type="checkbox"/> Yes <input type="checkbox"/> No Patient Education: Expected date: _____ <input type="checkbox"/> MD office <input type="checkbox"/> Barney's Specialty <input type="checkbox"/> Alternate program			
Prescription Information			
HARVONI® (ledipasvir/sofosbuvir) Directions: Take one tablet (90mg-400mg) PO daily Quantity: _____ Refills: _____		RIBAVIRIN <input type="checkbox"/> 200mg capsules <input type="checkbox"/> 200mg tablets Directions: Take _____ tabs/caps PO QAM and _____ tabs/caps PO QPM Quantity: _____ Refills: _____	
VIEKIRA PAK® (ombitasvir/paritaprevir/ritonavir/dasabuvir) Directions: Take two tablets (12.5mg/75mg/50mg) once daily (in the morning) and take one tablet (250 mg) twice daily (morning and evening) with a meal Quantity: _____ Refills: _____		DAKLINZA® (daclatasvir) <input type="checkbox"/> 30mg <input type="checkbox"/> 60mg Directions: Take one tablet PO daily with Sovaldi® Quantity: _____ Refills: _____	
SOVALDI® (sofosbuvir) Directions: Take 1 tablet (400mg) PO daily Quantity: _____ Refills: _____		TECHNIVIE® (ombitasvir/paritaprevir/ritonavir) Directions: Take two tablets PO daily in the morning Quantity: _____ Refills: _____	
ZEPATIER® (elbasvir/grazoprevir) Directions: Take 1 tablet (50/100) PO daily Quantity: _____ Refills: _____		EPCLUSA® (sofosbuvir/velpatazvir) Directions: Take one tablet (400mg/100mg) PO daily Quantity: _____ Refills: _____	
Patient Support Program: Please sign and date below to enroll in the pharmaceutical company assisted patient support programs and patient funding. PATIENT SIGNATURE: _____ Date: _____			
****By signing this form and utilizing our services, you are authorizing Barney's Specialty Pharmacy and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.****			
X _____ Dispense as written _____ Date		X _____ Substitution Permitted _____ Date	

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.